Inhaled dry powder formulations for treating tuberculosis

Area of Science:

• Pulmonary drug delivery
• Pharmaceutical formulation
• Infectious disease treatment

Background:

• Tuberculosis (TB) remains a leading infectious cause of death globally.
• Traditional oral antitubercular drug administration faces limitations in targeting efficacy.
• Pulmonary drug delivery via inhalers is emerging as a viable alternative.

Purpose of the Study:

• To review the current status of TB, its pathogenesis, and treatment strategies.
• To highlight the shortcomings of conventional drug delivery methods for TB.
• To explore the advantages and formulation approaches for pulmonary powder delivery in TB treatment.

Main Methods:

• Review of current literature on tuberculosis, drug delivery systems, and formulation techniques.
• Analysis of different pulmonary delivery devices, including dry powder inhalers (DPIs) and nebulizers.
• Discussion of particle engineering methods for DPI formulations (e.g., micronization, spray drying).

Main Results:

• Dry powder inhalers (DPIs) offer stability and user-friendliness over nebulizers for pulmonary drug delivery.
• Pulmonary delivery allows for direct targeting of alveolar macrophages, where TB bacteria reside.
• Various formulation approaches enable the engineering of micro- or nanoparticles for effective inhalation.

Conclusions:

• Pulmonary delivery of antitubercular drugs via DPIs presents a significant advancement over oral administration.
• This strategy can potentially improve treatment outcomes by achieving higher drug concentrations at the infection site.
• Further research into formulation and pharmacokinetic studies is crucial for optimizing inhaled TB therapies.